Literature DB >> 3069476

Digoxin-felodipine interaction in patients with congestive heart failure.

P H Dunselman1, A H Scaf, C E Kuntze, K I Lie, H Wesseling.   

Abstract

A possible interaction between felodipine and digoxin was studied in 23 patients with congestive heart failure before and after 8 weeks treatment with both drugs. A modest, non-significant increase in serum digoxin level 2 h postdose (+15%) was found in the felodipine group (n = 11) compared to placebo (n = 12), with no change in the trough and 6 h postdose levels. There was a bimodal distribution of the observed changes in serum digoxin level 2 h postdose: a significant increase (p less than 0.001) was observed only in patients with a high plasma felodipine level, which may have been caused by changes in the absorption rate in those patients. Changes in the elimination of digoxin after felodipine therapy appeared unlikely, since the trough and 6 h post-dose levels were unchanged. Analysis of the clinical characteristics, haemodynamics and laboratory values revealed no significant differences between the subgroups. The observed increase in serum digoxin warrants monitoring the trough and peak levels digoxin in patients with congestive heart failure who are also being treated with felodipine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3069476     DOI: 10.1007/bf00558239

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  Determinants of the renal clearance of digoxin.

Authors:  H Halkin; L B Sheiner; C C Peck; K L Melmon
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

2.  Pharmacokinetics of digoxin: relationship between response intensity and predicted compartmental drug levels in man.

Authors:  W G Kramer; A J Kolibash; R P Lewis; M S Bathala; J A Visconti; R H Reuning
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

3.  Renal tubular secretion of digoxin.

Authors:  E Steiness
Journal:  Circulation       Date:  1974-07       Impact factor: 29.690

4.  An improved method of digoxin therapy.

Authors:  R W Jelliffe
Journal:  Ann Intern Med       Date:  1968-10       Impact factor: 25.391

5.  Effects of nifedipine and diltiazem on plasma levels and renal excretion of beta-acetyldigoxin.

Authors:  J Kuhlmann
Journal:  Clin Pharmacol Ther       Date:  1985-02       Impact factor: 6.875

6.  Acute and chronic pharmacodynamic interaction of verapamil and digoxin in atrial fibrillation.

Authors:  J B Schwartz; D Keefe; R E Kates; E Kirsten; D C Harrison
Journal:  Circulation       Date:  1982-06       Impact factor: 29.690

7.  [Increased digitalis-like activity in combined administration of calcium antagonists and digitalis preparations].

Authors:  R De Cesaris; M Balestrazzi; R Chiarappa; G Ranieri
Journal:  G Ital Cardiol       Date:  1983-09

8.  Effect of nifedipine on serum digoxin concentration and renal digoxin clearance.

Authors:  J B Schwartz; P J Migliore
Journal:  Clin Pharmacol Ther       Date:  1984-07       Impact factor: 6.875

9.  Influence of atenolol and nifedipine on digoxin-induced inotropism in humans.

Authors:  P B Hansen; J Buch; O O Rasmussen; S Waldorff; E Steiness
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

10.  Effect of nifedipine on digoxin kinetics in healthy subjects.

Authors:  K E Pedersen; A Dorph-Pedersen; S Hvidt; N A Klitgaard; K Kjaer; F Nielsen-Kudsk
Journal:  Clin Pharmacol Ther       Date:  1982-11       Impact factor: 6.875

View more
  10 in total

Review 1.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK).

Authors:  Mitsuo Saito; Mutsuko Hirata-Koizumi; Shinji Miyake; Ryuichi Hasegawa
Journal:  Eur J Clin Pharmacol       Date:  2005-07-23       Impact factor: 2.953

Review 3.  Pharmacokinetic interactions with calcium channel antagonists (Part II).

Authors:  K D Schlanz; S A Myre; M B Bottorff
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

Review 4.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

5.  Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions.

Authors:  Harma Ellens; Shibing Deng; Joann Coleman; Joe Bentz; Mitchell E Taub; Isabelle Ragueneau-Majlessi; Sophie P Chung; Krisztina Herédi-Szabó; Sibylle Neuhoff; Johan Palm; Praveen Balimane; Lei Zhang; Masoud Jamei; Imad Hanna; Michael O'Connor; Dallas Bednarczyk; Malin Forsgard; Xiaoyan Chu; Christoph Funk; Ailan Guo; Kathleen M Hillgren; Libin Li; Anne Y Pak; Elke S Perloff; Ganesh Rajaraman; Laurent Salphati; Jan-Shiang Taur; Dietmar Weitz; Heleen M Wortelboer; Cindy Q Xia; Guangqing Xiao; Tetsuo Yamagata; Caroline A Lee
Journal:  Drug Metab Dispos       Date:  2013-04-25       Impact factor: 3.922

6.  Relationship of changes in felodipine pharmacokinetics to haemodynamics during chronic oral treatment of congestive heart failure patients.

Authors:  A H Scaf; P H Dunselman; H Wesseling
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

7.  Pharmacokinetic and pharmacodynamic aspects of concomitant mibefradil-digoxin therapy at therapeutic doses.

Authors:  J Peters; H A Welker; R Bullingham
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Apr-Jun       Impact factor: 2.441

Review 8.  Felodipine clinical pharmacokinetics.

Authors:  P H Dunselman; B Edgar
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

Review 9.  Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

10.  The interaction of the calcium antagonist RO 40-5967 with digoxin.

Authors:  M Siepmann; C Kleinbloesem; W Kirch
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.